Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.97 USD

102.97
668,578

-0.19 (-0.18%)

Updated Sep 24, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

by Zacks Equity Research

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock for Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Zacks Equity Research

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Zacks Equity Research

Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency

by Zacks Equity Research

Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Zacks Equity Research

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

by Zacks Equity Research

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Zacks Equity Research

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

by Zacks Equity Research

Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

by Zacks Equity Research

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Zacks Equity Research

Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.

Zacks Equity Research

Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

Zacks Equity Research

GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools

by Zacks Equity Research

GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.

Zacks Equity Research

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

by Zacks Equity Research

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Zacks Equity Research

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Zacks Equity Research

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

by Zacks Equity Research

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

Zacks Equity Research

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

by Zacks Equity Research

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

Zacks Equity Research

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Zacks Equity Research

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

Zacks Equity Research

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

by Zacks Equity Research

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Zacks Equity Research

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Zacks Equity Research

Illumina (ILMN) Extends Partnership to Advance Cancer Test

by Zacks Equity Research

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.